Lv4
480 积分 2024-07-01 加入
Allergic Rhinitis
8天前
已完结
Peristomal Pyoderma Gangrenosum Responding to Risankizumab
29天前
已完结
Are all the IL-23 blockers the same in inflammatory bowel disease?
1个月前
已完结
Targeting the Interleukin 23 Pathway in Inflammatory Bowel Disease
1个月前
已完结
Integrated Population Pharmacokinetic Analysis of Ustekinumab Across Multiple Immune-Mediated Inflammatory Disease Populations and Healthy Subjects
1个月前
已完结
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
1个月前
已完结
Are all the IL-23 blockers the same in inflammatory bowel disease?
1个月前
已完结
P1044 Mirikizumab Pharmacokinetics and Exposure-Response in a Phase 2 Study in Patients With Moderately to Severely Active Crohn’s Disease
2个月前
已关闭
S1052 Efficacy and Safety of Subcutaneous Guselkumab Induction Therapy in Patients With Moderately to Severely Active Crohn’s Disease: Results Through Week 48 From the Phase 3 GRAVITI Study
2个月前
已关闭
A Phase I Study to Evaluate the Safety and Pharmacokinetics of SHR0302 Base Ointment in Healthy Adult Volunteers
2个月前
已完结
皖公网安备34019202002308
